权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Discovery of Novel Epitopes for Antibody Dependent Cell-mediated Cytotoxicity Against HIV-1 Infected Cells

发现抗体依赖性细胞介导的针对 HIV-1 感染细胞的细胞毒性的新表位

基本信息

批准号：
10113530
负责人：
Cynthia Ann Derdeyn
金额：
$ 22.31万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-02-24 至 2022-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10113530
关键词：
AIDS/HIV problem Africa South of the Sahara Antibodies Antibody Response Antibody-mediated protection Antiviral Agents Autologous B-Lymphocytes Binding Biological Assay CCR5 gene Cell Separation Cells Collection Cryopreservation Detection Disease Progression Effector Cell Enrollment Epitopes Evaluation Event Genetic Glycocalyx Goals HIV HIV Envelope Protein gp120 HIV vaccine HIV-1 Heterosexuals Human Human Volunteers Individual Infection Maps Measures Mediating Mediator of activation protein Modeling Molecular Cloning Monoclonal Antibodies Patients Peripheral Blood Mononuclear Cell Phase Proteins Recombinants Research Rwanda Signal Transduction Site Statistical Data Interpretation Surface Testing Vaccinated Vaccination Vaccines Variant Viral Virion Virus Zambia antibody-dependent cell cytotoxicity base cohort cross reactivity efficacy trial innovation insight neutralizing antibody nonhuman primate novel response simian human immunodeficiency virus transmission process vaccine efficacy vaccine trial

项目摘要

Project Summary/Abstract HIV research efforts are strongly focused on developing vaccines that can elicit highly protective antibody responses. There is evidence from human and nonhuman vaccine studies that both neutralizing and non- neutralizing antibody activities contribute to protection against acquisition. Importantly, the only phase III vaccine efficacy trial to show a signal of protection in human volunteers demonstrated that antibody dependent cell- mediated cytotoxicity (ADCC) was associated with reduced acquisition, compelling us to know more about this Fc-mediated antiviral function. We previously recovered a unique collection of more than 300 monoclonal antibodies from 6 recently HIV-1 infected individuals from Zambia and Rwanda and found that a subset of these antibodies mediated ADCC against target cells coated with the envelope gp120 protein from the autologous, transmitted/founder (T/F) variant. This activity was associated with antibodies that had shorter CDRH3 regions and lower neutralization activity against the T/F envelope pseudovirus than antibodies lacking ADCC activity. Modeling and competition studies suggested that some of the ADCC-mediating antibodies recognize novel epitopes. Here, we will test these monoclonal antibodies for ADCC against target cells infected with the authentic T/F variant created by molecular cloning, and compare the results with ADCC against target cells coated with the T/F gp120 protein and neutralization of the T/F Env, the latter being the hallmark of antibody binding to the functional, virion-associated envelope spike. By using a large number of autologous T/F envelope-antibody combinations, where the envelope presents the exact epitope or a very close approximation to that which the antibody was selected against, and two widely used ADCC assays, our studies have the potential to reveal previously unappreciated mechanistic features of ADCC and identify novel epitopes that can be further developed and explored for vaccines.

项目总结/文摘